Literature DB >> 10492157

Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells.

T Ohara1, T Arakawa.   

Abstract

We examined the effects of lansoprazole, a proton-pump inhibitor, on peripheral blood mononuclear cells in healthy subjects in comparison with ranitidine. Ten healthy volunteers were randomly divided into two groups and given either lansoprazole (30 mg daily for 2 days) or ranitidine (150 mg daily for 21 days). Peripheral blood was collected before and 7, 14, and 21 days after the start of treatment. Mononuclear cells were isolated by densitometric centrifugation and were examined for adhesion molecules (ICAM-1, VLA4, SLe(x)), membrane markers of the monocyte/macrophage series, and lymphocyte phenotypes. The number of cells expressing adhesion molecules, the number of monocytes/macrophages, and lymphocyte phenotypes were the same in Helicobacter pylori-positive and -negative subjects. The number of cells expressing ICAM-1 was significantly decreased seven days after the start of lansoprazole treatment, and this change persisted until day 14, while ranitidine had no effect. The number of monocytes (identified by Leu-M3 positivity) was decreased seven days after the start of treatment in both groups, but predominantly in the lansoprazole group. No other changes were observed on administration of either drug. These results suggest that short-term treatment with lansoprazole causes persistent inhibition of inflammatory responses irrespective of the presence of H. pylori infection. This effect may indicate a possible new mechanism of action of proton-pump inhibitors other than inhibition of acid secretion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492157     DOI: 10.1023/a:1026604203237

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.

Authors:  J Labenz; A L Blum; E Bayerdörffer; A Meining; M Stolte; G Börsch
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3.

Authors:  S Sugawara; T Abo; K Kumagai
Journal:  J Immunol Methods       Date:  1987-06-26       Impact factor: 2.303

3.  Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2.

Authors:  M Satoh; S Seki; W Hashimoto; K Ogasawara; T Kobayashi; K Kumagai; S Matsuno; K Takeda
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

4.  Six months of omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: a multicenter, prospective, comparative study. Interdisciplinary Group for Ulcer Study.

Authors: 
Journal:  Digestion       Date:  1995       Impact factor: 3.216

5.  Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta.

Authors:  T Watanabe; T Arakawa; T Fukuda; K Higuchi; K Kobayashi
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

6.  Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection.

Authors:  L A Noach; N B Bosma; J Jansen; F J Hoek; S J van Deventer; G N Tytgat
Journal:  Scand J Gastroenterol       Date:  1994-05       Impact factor: 2.423

7.  Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?

Authors:  E Hoshino; N Umeda; J Sano; K Miki; N Yahagi; M Oka; M Kimura; H Miyashita
Journal:  J Clin Gastroenterol       Date:  1995       Impact factor: 3.062

8.  Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis.

Authors:  J E Crabtree; T M Shallcross; R V Heatley; J I Wyatt
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

9.  Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection.

Authors:  J E Crabtree; P Peichl; J I Wyatt; U Stachl; I J Lindley
Journal:  Scand J Immunol       Date:  1993-01       Impact factor: 3.487

10.  Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats.

Authors:  L Santucci; S Fiorucci; F M Di Matteo; A Morelli
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

View more
  16 in total

1.  Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

Authors:  Janet T Holbrook; Robert A Wise; Benjamin D Gold; Kathryn Blake; Ellen D Brown; Mario Castro; Allen J Dozor; John J Lima; John G Mastronarde; Marianna M Sockrider; W Gerald Teague
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

2.  Therapy with omeprazole modulates regulatory T cell/T helper 17 immune response in children with duodenal ulcers.

Authors:  Chuan-Ying Li; Cheng Wu
Journal:  Inflammopharmacology       Date:  2017-07-22       Impact factor: 4.473

3.  Suppression of proinflammatory cytokine production in macrophages by lansoprazole.

Authors:  Akinari Hinoki; Kazunori Yoshimura; Keiko Fujita; Masumi Akita; Rie Ikeda; Masabumi Nagashima; Masahiko Nomura; Akira Satomi
Journal:  Pediatr Surg Int       Date:  2006-11       Impact factor: 1.827

Review 4.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 5.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine.

Authors:  Cristina Pozzoli; Alessandro Menozzi; Daniela Grandi; Elvira Solenghi; Maria C Ossiprandi; Chiara Zullian; Simone Bertini; Giulia M Cavestro; Gabriella Coruzzi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-12-07       Impact factor: 3.000

7.  Eosinophilic esophagitis: interactions with gastroesophageal reflux disease.

Authors:  Edaire Cheng; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

8.  In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-κB and activator protein-1.

Authors:  Xiaofang Huo; Xi Zhang; Chunhua Yu; Qiuyang Zhang; Edaire Cheng; David H Wang; Thai H Pham; Stuart J Spechler; Rhonda F Souza
Journal:  Gut       Date:  2013-09-18       Impact factor: 23.059

9.  Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.

Authors:  Hiroshi Ichikawa; Norimasa Yoshida; Tomohisa Takagi; Naoya Tomatsuri; Kazuhiro Katada; Yutaka Isozaki; Kazuhiko Uchiyama; Yuji Naito; Takeshi Okanoue; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 10.  Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.

Authors:  Ramalinga R Kedika; Rhonda F Souza; Stuart Jon Spechler
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.